Payment overview · 2025
General Payments
2 reported records · 2 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1518078286
Verified facts
CMS Open Payments records show Youssef Alraei, MD received $59.68 in general payments during 2025 across 2 reported records.
Lilly USA, LLC accounted for 75.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
2 reported records · 2 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 75.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.68 | 24.6% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Education | $45.00 | 1 |
| Food and Beverage | $14.68 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
189 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 136 |
| Metformin Hcl | Metformin Hcl | 479 | 102 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 469 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 321 | 75 |
| Omeprazole | Omeprazole | 315 | 58 |
| Gabapentin | Gabapentin | 287 | 57 |
| Simvastatin | Simvastatin | 252 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 58 |
| Ozempic | Semaglutide | 237 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 219 | 49 |
| Enalapril Maleate | Enalapril Maleate | 193 | 37 |
| Jardiance | Empagliflozin | 189 | 36 |
| Januvia | Sitagliptin Phosphate | 182 | 32 |
| Famotidine | Famotidine | 179 | 57 |
| Vascepa | Icosapent Ethyl | 174 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 38 |
| Atenolol | Atenolol | 161 | 35 |
| Losartan Potassium | Losartan Potassium | 150 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 33 |
| Montelukast Sodium | Montelukast Sodium | 146 | 27 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 141 | 29 |
| Lisinopril | Lisinopril | 136 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 24 |
| Glipizide Er | Glipizide | 123 | 32 |
| Alendronate Sodium | Alendronate Sodium | 120 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 116 | 35 |
| Azithromycin | Azithromycin | 114 | 73 |
| Donepezil Hcl | Donepezil Hcl | 114 | 22 |
| Linzess | Linaclotide | 112 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 98 | 14 |
| Finasteride | Finasteride | 93 | 25 |
| Ibuprofen | Ibuprofen | 92 | 29 |
| Glimepiride | Glimepiride | 82 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 26 |
| Meloxicam | Meloxicam | 73 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 15 |
| Allopurinol | Allopurinol | 59 | 11 |
| Promethazine Hcl | Promethazine Hcl | 59 | 36 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | 15 |
| Fenofibrate | Fenofibrate | 56 | 12 |
| Meclizine Hcl | Meclizine Hcl | 51 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | suppressed |
| Acarbose | Acarbose | 47 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 47 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 18 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 45 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 17 |
| Eliquis | Apixaban | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | 13 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Alprazolam | Alprazolam | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 39 | 14 |
| Ezetimibe | Ezetimibe | 37 | 11 |
| Metformin Hcl Er | Metformin Hcl | 37 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 19 |
| Creon | Lipase/Protease/Amylase | 35 | suppressed |
| Furosemide | Furosemide | 35 | 11 |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 34 | suppressed |
| Procto-Med Hc | Hydrocortisone | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Folic Acid | Folic Acid | 31 | suppressed |
| Proctozone-Hc | Hydrocortisone | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Mupirocin | Mupirocin | 29 | 11 |
| Methimazole | Methimazole | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 27 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 27 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Trulance | Plecanatide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 16 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | 13 |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Renvela | Sevelamer Carbonate | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | 11 |
| Digoxin | Digoxin | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Glipizide Xl | Glipizide | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Crestor | Rosuvastatin Calcium | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $59.68 · 2 records | Lilly USA, LLC | REPATHA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error